About Novelogics Biotechnology

About company

They are a pre-clinical stage biotech company developing innovative antibody immunotherapies for cancer using a novel “Interceptor” approach. Our antibodies bind only to specific immunosuppressive proteins that are released from cancer cells (soluble ligands), and not to the cell surface-bound versions. This treatment is predicted to be effective towards multiple types of cancers and has safety built into the design of the drug, thereby minimizing the likelihood of unwanted side effects. Our current studies have demonstrated efficacy in repeated prostate cancer models in mice.